Pharmaceuticals
Pharma - API
from 407 today
Aarti Drugs delivered a strong quarter in Q1FY27, driven by higher realizations amid the Middle East war, volume growth, and the successful ramp-up of new facilities, leading to an upgraded target price of Rs 515 and a BUY rating.
Ratings and target prices as published by each firm. Each summary condenses that firm's stated view in its own note and is attributed to it; no report text is reproduced.
